A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

To be considered for this study, children and teenagers generally need to be between 2 and 17 years old and have moderate to severe eczema that has been diagnosed for a certain length of time (at least 6 or 12 months, depending on their age). Their eczema should not have responded well to creams applied to the skin in the past six months.

There are also some reasons why someone might not be able to join. For example, if they have other serious skin conditions like psoriasis or lupus, or if their eczema is very severe and often requires hospital stays. Children who have had a type of eczema infection called eczema herpeticum recently, or have had it multiple times, would not be suitable.

Also, if a child needs treatment for other serious illnesses, has certain infections, or has previously taken a similar type of oral eczema medicine, they might not be able to participate. It's important to discuss your child's full medical history with the study team to see if they meet all the requirements.

If your child takes part, they will receive either the study medicine (baricitinib), a dummy pill (placebo), or their usual steroid creams. The study team will regularly check your child's skin and overall health through appointments and assessments. This will involve physical examinations, questionnaires, and possibly blood tests.

You will need to make sure your child uses moisturising creams (emollients) daily throughout the study. Certain other eczema treatments might need to be stopped before and during the study. The total duration of participation isn't specified but typically involves regular visits over several months.